SCHEMBL5159446

SCHEMBL5159446

COc1ccc(-c2c(-c3cc(Cl)ccc3OC)c3cc(C(F)(F)F)ccc3[nH]c2=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 6/20 0.66
CSF1R P07333 1/20 0.51
MAP2 P11137 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
PIK3CA P42336 1/20 0.43
CCNB2 O95067 2/20 0.42
CDK1 P06493 2/20 0.42
CCNB1 P14635 2/20 0.42
GSK3B P49841 2/20 0.42
CDK5 Q00535 2/20 0.42
CDK5R1 Q15078 2/20 0.42
CCNB3 Q8WWL7 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5157642 0.91 CYP2C9 (0.65) CYP2C9CSF1RMAP2CYP1A2CYP3A4
SCHEMBL5160611 0.88 CYP2C9 (0.61) CYP2C9CSF1RCYP1A2CYP3A4CYP2D6
SCHEMBL5157415 0.85 CYP2C9 (0.73) CYP2C9CSF1RMAP2CYP1A2CYP3A4
SCHEMBL5161736 0.84 CYP2C9 (0.71) CYP2C9CSF1RMAP2CYP1A2CYP3A4
SCHEMBL5157933 0.83 CYP2C9 (0.60) CYP2C9CSF1RMAP2CYP1A2CYP3A4
SCHEMBL7487055 0.83 CYP2C9 (0.73) CYP2C9CSF1RMAP2CYP1A2CYP3A4
SCHEMBL5418072 0.83 CYP2C9 (0.70) CYP2C9MAP2CYP1A2CYP3A4CYP2D6
SCHEMBL5843990 0.82 CYP2C9 (0.61) CYP2C9CSF1RCYP1A2CYP3A4CYP2D6
SCHEMBL8476301 0.82 CYP2C9 (0.61) CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL8482038 0.82 CYP2C9 (0.68) CYP2C9MAP2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1133474-B1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-02-21 EP claimed
US-6184231-B1 NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION BRISTOL-MYERS SQUIBB 2001-02-06 US claimed
EP-1133474-B1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-02-21 EP disclosed
US-6184231-B1 NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION BRISTOL-MYERS SQUIBB 2001-02-06 US disclosed